AstraZeneca
Last updated Jun 16, 2026
Evidence Sources
11
Competitive Findings
3
Portfolio Developments
16
Regulatory Precedents
8
Clinical Programs
3
Confidence Coverage
70%
Audit
- Competitor findings: 3
- Portfolio developments: 16
- Self-competition findings removed: 20
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Lung Cancer
- B-cell Non-Hodgkin Lymphoma
- Immunotherapy
- AKT Inhibitor
Highest priority development: TALZENNA Plus XTANDI Shows 52% rPFS Improvement in Metastatic Prostate Cancer
Portfolio development
TALZENNA Plus XTANDI Shows 52% rPFS Improvement in Metastatic Prostate Cancer is an owned AstraZeneca portfolio development in Oncology · Prostate Cancer.
Competitive pressure: High
Portfolio impact: High
Evidence coverage: 70%
Active Signals
123
Investigate Priority
22
Opportunity Score
51892
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- InvestigateJun 16, 2026Score 434FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns
Oncology · Breast Cancer
- MonitorJun 16, 2026Score 431Saphnelo Self-Administration Approved in the US for SLE Treatment
Immunology · Systemic Lupus Erythematosus
- MonitorJul 6, 2026Score 430FDA Accepts BLA for Anifrolumab by AstraZeneca
Immunology · Systemic Lupus Erythematosus
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)Humanexa SignalsPfizerPortfolio
- Low Confidence · 0%Sources (3)AstraZenecaPfizerPortfolio
- Low Confidence · 0%Sources (3)AstraZenecaPfizerPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
- Enhertu recommended in EU for HER2+ solid tumoursHigh Confidence · 95%
Elevated competitive pressure
Sources (2)AstraZenecaCompetitiva - AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class TreatmentHigh Confidence · 95%
Elevated competitive pressure
Sources (2)Humanexa SignalsCompetitiva - Enhertu approved in two HER2+ early BC settingsLow Confidence · 59%
Potential competitive pressure
Sources (2)AstraZenecaCompetitiva
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Other | Cancer Accelerated ApprovalsLow Confidence · 54%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Verified Clinical Benefit | Cancer Accelerated ApprovalsLow Confidence · 54%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancerModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancerModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Enhertu recommended in EU for HER2+ solid tumoursModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class TreatmentModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - Enhertu approved in two HER2+ early BC settingsModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- InvestigateScore 434FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns
Oncology · Breast Cancer
- InvestigateScore 429Imfinzi + EV shows significant survival benefits in muscle-invasive bladder cancer
Oncology · Bladder Cancer
- EscalateScore 428FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Oncology · Prostate Cancer
- EscalateScore 428Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to AstraZeneca right now?
- Which regulatory precedents should AstraZeneca monitor in Oncology and Lung Cancer?
- How does Enhertu recommended in EU for HER2+ solid tumours compare to the nearest competitive programs?
- What signals require immediate investigation for AstraZeneca?
- Summarize the strategic implications of recent developments for AstraZeneca.
- Where is the greatest uncertainty in AstraZeneca's competitive positioning?